CClinicalTrials.gg
CompletedNCT05018000CAFEUpdated Jan 12, 2026

Cancer Financial Experience

An interventional study of Financial navigation and Enhanced usual care in Cancer, sponsored by Kaiser Permanente. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Kaiser Permanente · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
371
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a randomized clinical trial designed to test a novel financial navigation intervention. The study assesses the impact of the financial navigation intervention on financial hardship and health-related quality of life, cancer-related material and psychological financial hardship, patient-centered communication, and time to initiation of treatment.

Read the detailed description

Rationale:

Up to half of people with cancer experience financial hardship. Cancer-related financial hardship is associated with several adverse intermediate and health outcomes, including poor quality of life, treatment non-adherence, and lower survival.

Observational evidence suggests that communication about financial concerns and out-of-pocket (OOP) costs early in the treatment trajectory and in partnership with the care team could help to prevent or lessen financial hardship. This type of communication could be delivered through patient navigation programs and is consistent with both patient and care team preferences.

However, to date there is no evidence from randomized trials showing the impact of financial navigation during the active treatment on financial hardship. Further, no intervention-based studies have provided evidence on the most effective ways to mitigate cancer-related financial hardship.

Background:

As costs of cancer care in U.S. have risen over time, so has the burden of out-of-pocket (OOP) costs and indirect costs such as travel, employment changes, and caregiver costs. These cumulative costs pose increased financial risk for people diagnosed with cancer. Despite a patient's health insurance status, financial hardship from cancer care is prevalent: 47%-49% of cancer survivors report financial hardship and 12%-62% of cancer survivors report debt due to treatment costs. Financial hardship is associated with decreased treatment initiation and adherence, poor symptoms and quality of life, and increased mortality risk, so preventing or mitigating its effects is a clinical imperative.

Integration of cost of cancer care information into conversations between patients and clinicians can optimize medical decision-making and reduce the risk of financial hardship, and is consistent with high-quality cancer care and patient preferences. Patient understanding of OOP costs can assist with planning and budgeting, and can facilitate early connection with financial support services that may help to mitigate the financial burden of cancer care. Yet, less than one in five patients report having cost discussions. Consequently, many patients are uninformed about the costs of their cancer care and face unexpected OOP costs, with important consequences for material (e.g., debt), psychological (e.g., cost-related distress), and behavioral (e.g. treatment adherence) financial hardship.

There is an urgent need for evidence-based interventions on how to prevent or mitigate financial hardship for people with cancer. While the extent of financial hardship as a toxicity of cancer care is increasingly well-documented, there is limited evidence to date as to what types of interventions can mitigate or prevent financial hardship due to cancer care. Policy, societal, and organizational-level interventions, such as those focused on bending the curve of rising health care cost or improving price transparency to ordering providers are all needed, but these may take a long time or show limited effect. In the meantime, patients continue to need assistance navigating, managing and anticipating OOP costs, and patient- and team level-interventions such as the CAFÉ study may hold promise for this purpose.

02

Conditions studied

  • Cancer

Keywords

  • financial hardship
  • cancer
  • health outcomes
03

In context

Neoplasms

9,359 studies on the registry are indexed under Neoplasms; 2,486 are open to participants now.

This study's enrollment of 371 is above the median of 50 across 7,250 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Kaiser Permanente is the lead sponsor of 385 studies on the registry; 41 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. KPNW and KPWA members with a new cancer diagnosis (within the past 120 days from identification date)
  2. 18+ years of age (based on age at time of identification date)
  3. Recent visit to CAFÉ clinic/department
  4. Current, living member as of identification date
  5. Continuous enrollment at least 6 months prior to identification date
  6. English speaker for KPWA; English or Spanish speaker for KPNW

Exclusion criteria

Exclusion Criteria:

  1. On do-not contact list at KP
  2. Cancer diagnosis is for non-melanoma skin cancer
  3. Cancer diagnosis is for a benign or in situ tumor
  4. Hospice referral in past year
  5. Self or household member has already enrolled or completed participation in CAFÉ pilot study or main trial.
  6. Unable to complete survey
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
371 participants (actual)

Study arms

  • Active comparator
    Arm 1: Enhanced usual care

    Participants in this arm will receive their usual care plus a Financial Resource Sheet. The financial resource sheet lists and describes existing organization and community resources available to KP members.

    Behavioral: Enhanced usual care

  • Experimental
    Arm 2: Brief financial navigation intervention

    Participants in this arm will receive their usual care, and the Financial Resource Sheet described in Arm 1, plus one (1) cycle of financial navigation (total cycles: 1; total length: 6 months). In each intervention cycle participants will get at least one (1) phone call with a CAFÉ Financial Navigator, the navigator will talk with participants to identify financial questions or concerns. The navigator will create a personalized plan for each participant. Participants can request extra support from the navigator for up to 6 months.

    Behavioral: Financial navigation

  • Experimental
    Arm 3: Extended financial navigation intervention

    Participants in this arm will receive their usual care, a Financial Resource Sheet and the brief intervention described in Arm 2 (i.e., one (1) cycle of financial navigation). Plus, they will receive two (2) additional cycles of financial navigation (total cycles: 3; total length: 6 months).

    Behavioral: Financial navigation

Interventions

  • BehavioralFinancial navigation

    The CAFÉ intervention is a financial navigation intervention. During the Intervention, a CAFÉ financial navigator will provide information support and resources to people with cancer after diagnosis. CAFÉ intervention components include: (1) proactive assessment of patient financial questions and concerns (e.g., acute financial need or inability to pay for household expenses; deciding between care options depending on cost; uncertainty around planning for out of pocket costs and/or when patients will need to pay), (2) proactive, personalized support and referrals.

  • BehavioralEnhanced usual care

    The financial resource sheet lists and describes existing internal and community resources available to KP members

06

What researchers measure

Primary outcomes

  1. Financial distress

    InCharge Financial Distress/Financial Well-Being Scale. This is a validated, 8-item scale that assesses current ability to meet financial obligations, stress or worry about finances, and satisfaction with present financial situation. It is scored to a 10-point scale, where 1 is "Overwhelming financial distress/lowest financial well-being," and 10 is "No financial distress/highest financial well-being." It has been validated in multiple populations and national norms are provided.

    Time frame: baseline and 12 months

  2. Health-related quality of life (cancer specific)

    The FACT-G7 is a 7-item version of the Functional Assessment of Cancer Therapy-General (FACT-G), a patient-reported outcome measure used to assess health-related quality of life in patients undergoing cancer therapy. The survey assesses the impacts of cancer therapy in four domains: physical, social/family, emotional, and functional. Higher scores represent higher quality of life.

    Time frame: baseline and 12 months

Secondary outcomes

  1. Financial hardship due to cancer care costs

    Items from the Medical Expenditure Panel Survey (Yabroff 2016): Material financial hardship items: Have you or has anyone in your family had to borrow money or go into debt because of your cancer, its treatment or the lasting effects of that treatment? (Yes\\No) Did you or your family ever file for bankruptcy because of your cancer, its treatment, or the lasting effects of that treatment? (Yes\\No) Have you or your family had to make any other kinds of financial sacrifices because of your cancer, its treatment, or the lasting effects of that treatment? (Yes\\No) Please think about medical care visits for cancer, its treatment, or the lasting effects of that treatment. Have you ever been unable to cover your share of those visits? (Yes\\No) Psychological financial hardship item: Have you ever worried about having to pay large medical bills related to your cancer? (Yes\\No)

    Time frame: baseline and 12 months

Other outcomes

  1. Initiation of cancer treatment

    Proportion of patients initiating treatment, including radiation, surgery, and systemic therapy.

    Time frame: between baseline and 12 months

  2. Time to initiation of cancer treatment

    Defined as the number of days between: 1) date of diagnosis/recurrence and start of first-line treatment. Censoring events will include disenrollment, death, and end of the study, whichever comes first.

    Time frame: between baseline and 12 months

  3. Use of medical financial assistance (MFA)

    Proportion of participants who enrolled in the Kaiser Permanente MFA program within 12 months following baseline

    Time frame: between baseline and 12 months

  4. Delinquent account

    Proportion of participants whose medical billing account is administratively marked as past due within 12 months following baseline

    Time frame: between baseline and 12 months

  5. Out of pocket (OOP) expenditures

    Average OOP expenditures per patient between baseline and 12 months following baseline

    Time frame: between baseline and 12 months

  6. Patient Assessment of cancer Communication Experiences (PACE)

    16-item instrument intended to assess patient perspective on communication over the course of cancer care. The survey items are conceptually grounded in the 6 functions of patient-centered communication: fostering healing relationships, effectively exchanging information, responding to emotions, making quality decisions, managing uncertainty, and enabling patient self-care.

    Time frame: between baseline and 12 months

07

Study locations

1 site
  • Kaiser Permanente Washington Health Research Institute
    Seattle, Washington 98101, United States
08

References and documents

Publications

  • Henrikson NB, Anderson ML, Dickerson J, Petrik AF, Figueroa Gray M, Ewing JJ, Garcia R, Keast E, King DA, Locher B, Scrol A, Ramaprasan A, Rivelli JS, Schneider JL, Banegas MP. Financial Navigation for People Newly Diagnosed With Cancer: Primary Outcomes From the Cancer Financial Experience Randomized Trial. JCO Oncol Pract. 2025 Dec;21(12):1817-1829. doi: 10.1200/OP-25-00874. Epub 2025 Oct 10. PubMed 41070850 ↗
  • Henrikson NB, Anderson ML, Dickerson J, Ewing JJ, Garcia R, Keast E, King DA, Lewis C, Locher B, McMullen C, Norris CM, Petrik AF, Ramaprasan A, Rivelli JS, Schneider JL, Shulman L, Tuzzio L, Banegas MP. The Cancer Financial Experience (CAFE) study: randomized controlled trial of a financial navigation intervention to address cancer-related financial hardship. Trials. 2022 May 13;23(1):402. doi: 10.1186/s13063-022-06344-3. PubMed 35562781 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05018000
Lead sponsor
Kaiser Permanente
Responsible party
Sponsor
First posted
Aug 24, 2021
Start date
Aug 11, 2021
Primary completion
Mar 1, 2025
Completion
Aug 31, 2025
Last update
Jan 12, 2026

Study contacts

Nora B Henrikson, PhD, MPH
principal investigator · Kaiser Permanente
Matthew Banegas, PhD, MPH, MS
principal investigator · University of California, San Diego
Amanda Petrik, PhDC, MS
principal investigator · Kaiser Permanente

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion